BRPI0409492A - terapias de combinação - Google Patents

terapias de combinação

Info

Publication number
BRPI0409492A
BRPI0409492A BRPI0409492-1A BRPI0409492A BRPI0409492A BR PI0409492 A BRPI0409492 A BR PI0409492A BR PI0409492 A BRPI0409492 A BR PI0409492A BR PI0409492 A BRPI0409492 A BR PI0409492A
Authority
BR
Brazil
Prior art keywords
compounds
combination therapies
receptor agonists
pharmaceutical agent
inhibitors
Prior art date
Application number
BRPI0409492-1A
Other languages
English (en)
Inventor
Robert Everett Manning
Ivan Michael Richards
Original Assignee
Pharmacia & Up John Company Ll
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia & Up John Company Ll filed Critical Pharmacia & Up John Company Ll
Publication of BRPI0409492A publication Critical patent/BRPI0409492A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/14—Quaternary ammonium compounds, e.g. edrophonium, choline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

"TERAPIAS DE COMBINAçãO". A presente invenção refere-se a um método de tratamento da asma, DPOC, rinite alérgica e rinite infeciosa através da administração de um primeiro agente farmacêutico incluindo um ou mais compostos selecionados de entre os compostos de amínio quaternário das fórmulas I-V e um segundo agente farmacêutico incluindo um ou mais agentes farmacêuticos selecionados entre os agonistas dos receptores A~ 2A~ da adenosina, agonistas dos receptores D2 da dopamina, inibidores da fosfodiesterase (PDE), corticosteróides, inibidores da recaptação da norepinefrina, 4-hidróxi-7-¢2-¢2-¢3-¢2-fenile-toxipropilsulfoniletilamino!etil!-1,3-benzoti azol-2(3H)-ona e seus sais farmaceuticamente aceitáveis e compostos antimuscarínicos não-quaternizados.
BRPI0409492-1A 2003-04-18 2004-04-05 terapias de combinação BRPI0409492A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US46397503P 2003-04-18 2003-04-18
PCT/IB2004/001170 WO2004091596A2 (en) 2003-04-18 2004-04-05 Combination therapies for chronic obstructive pulmonary disease (copd)

Publications (1)

Publication Number Publication Date
BRPI0409492A true BRPI0409492A (pt) 2006-05-02

Family

ID=33300101

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0409492-1A BRPI0409492A (pt) 2003-04-18 2004-04-05 terapias de combinação

Country Status (7)

Country Link
US (1) US20040209916A1 (pt)
EP (1) EP1620083A2 (pt)
JP (1) JP2006523674A (pt)
BR (1) BRPI0409492A (pt)
CA (1) CA2522666A1 (pt)
MX (1) MXPA05011225A (pt)
WO (1) WO2004091596A2 (pt)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20060272A1 (es) 2004-05-24 2006-05-22 Glaxo Group Ltd (2r,3r,4s,5r,2'r,3'r,4's,5's)-2,2'-{trans-1,4-ciclohexanodiilbis-[imino(2-{[2-(1-metil-1h-imidazol-4-il)etil]amino}-9h-purin-6,9-diil)]}bis[5-(2-etil-2h-tetrazol-5-il)tetrahidro-3,4-furanodiol] como agonista a2a
JP2008532973A (ja) * 2005-03-09 2008-08-21 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 抗コリン作用薬とｐｄｅ５−阻害剤に基づく新規な医薬組成物
JP2008542332A (ja) * 2005-05-31 2008-11-27 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 呼吸器疾患治療用新規医薬組成物
GB0514809D0 (en) 2005-07-19 2005-08-24 Glaxo Group Ltd Compounds
WO2007045979A1 (en) * 2005-10-19 2007-04-26 Ranbaxy Laboratories Limited Pharmaceutical compositions of muscarinic receptor antagonists
CN101454304B (zh) * 2006-05-24 2012-05-30 辉瑞有限公司 用于制造苯并吡喃-2-醇衍生物的方法
CA2723372A1 (en) * 2008-05-05 2009-11-12 University Of Rochester Methods and compositions for the treatment or prevention of pathological cardiac remodeling and heart failure
WO2010010464A2 (en) * 2008-07-21 2010-01-28 Actavis Group Ptc Ehf Fesoterodine substantially free of dehydroxy impurity
BRPI1009828A2 (pt) 2009-03-24 2019-03-12 Novartis Ag adjuvante de proteína de ligação de fator h meningocócica

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1670694B2 (de) * 1966-05-05 1976-07-22 Hoechst Ag, 6000 Frankfurt Verfahren zur herstellung von tetrahydroisochinolinen
NL6717123A (pt) * 1966-12-29 1968-07-01
US3505337A (en) * 1967-12-22 1970-04-07 Boehringer Sohn Ingelheim N - hydrocarbyl-substituted noratropinium,haloalkylates and o-acyl derivatives thereof
US3712890A (en) * 1969-06-20 1973-01-23 Ici Ltd Process for making 2-aryloxymethyl morpholines
US3891644A (en) * 1971-01-11 1975-06-24 Wyeth John & Brother Ltd 10,10-Disubstituted-2,3,4,10-tetrahydro-and 1,2,3,4,10a-hexahydropyrimidol {8 1,2-a{9 indole derivatives
US3904617A (en) * 1972-10-12 1975-09-09 Ayerst Mckenna & Harrison Process for preparing new heterocyclic derivatives
SE378109B (pt) * 1972-05-19 1975-08-18 Bofors Ab
US3995052A (en) * 1973-07-09 1976-11-30 Ayerst Mckenna And Harrison Ltd. Indenopyran- and indenothiopyranalkylamines III in the treatment of depression
GB1450137A (en) * 1973-12-20 1976-09-22 Wyeth John & Brother Ltd Indole derivatives
GB1450543A (en) * 1973-12-20 1976-09-22 Wyeth John & Brother Ltd Indole derivatives
US4314081A (en) * 1974-01-10 1982-02-02 Eli Lilly And Company Arloxyphenylpropylamines
US4118394A (en) * 1976-10-18 1978-10-03 Ayerst, Mckenna & Harrison Limited Pyrano- and thiopyranoindole derivatives
CS207624B2 (en) * 1977-06-24 1981-08-31 Lipha Method of making the substituted lactanes of the hexahydro-benzopyrano-3,2-c pyridin vinegar acids
IL56369A (en) * 1978-01-20 1984-05-31 Erba Farmitalia Alpha-phenoxybenzyl propanolamine derivatives,their preparation and pharmaceutical compositions comprising them
PH24267A (en) * 1980-02-15 1990-05-29 Glaxo Group Ltd Androstane carbothioates and pharmaceutical compositions containing the same
EP0057401B1 (en) * 1981-02-02 1984-08-01 Schering Corporation Aromatic heterocyclic esters of steroids, their preparation and pharmaceutical compositions containing them
FR2508035A1 (fr) * 1981-06-23 1982-12-24 Fabre Sa Pierre Derives d'aryl-1-aminomethyl-2 cyclopropanes carboxamides (z), leur preparation et leur application en tant que medicaments utiles dans le traitement des troubles du systeme nerveux central
US4535186A (en) * 1983-04-19 1985-08-13 American Home Products Corporation 2-Phenyl-2-(1-hydroxycycloalkyl or 1-hydroxycycloalk-2-enyl)ethylamine derivatives
KR920003065B1 (ko) * 1984-04-24 1992-04-13 글락소 그룹 리미티드 벤조디옥시노피롤 유도체의 제조방법
US4622398A (en) * 1985-06-24 1986-11-11 Eli Lilly And Company Dialkylaminotetrahydroquinazoline
US4956388A (en) * 1986-12-22 1990-09-11 Eli Lilly And Company 3-aryloxy-3-substituted propanamines
US5382600A (en) * 1988-01-22 1995-01-17 Pharmacia Aktiebolag 3,3-diphenylpropylamines and pharmaceutical compositions thereof
GB8906166D0 (en) * 1989-03-17 1989-05-04 Pfizer Ltd Therapeutic agents
DE3923675A1 (de) * 1989-07-18 1991-01-24 Basf Ag Amonoalkylsubstituierte 2-aminothiazole und diese enthaltende therapeutische mittel
US5633376A (en) * 1990-12-28 1997-05-27 Neurogen Corporation Certain aminomethyl phenylimidazole derivatives; and 4-aryl substituted piperazinyl and piperidinylmethyl phenylimidazole derivatives; a new class of dopamine receptor subtype ligands
US5235055A (en) * 1992-09-02 1993-08-10 American Home Products Corporation Antipsychotic quinoline derivatives of benzodioxanmethylamine
US5552407A (en) * 1993-06-11 1996-09-03 New York University Medical Center Anhydroecgonine compounds and their use as anticholinergic agents
US5382596A (en) * 1993-08-05 1995-01-17 Whitby Research, Inc. Substituted 2-aminotetralins
IT1271411B (it) * 1993-09-14 1997-05-28 Zambon Spa Derivati del 2-ammino-1,2,3,4-tetraidro-naftalene attivi sul sistema cardiovascolare
IT1271007B (it) * 1994-09-13 1997-05-26 Zambon Spa Derivati del 2-ammino-1,2,3,4-tetraidronaftalene attivi sul sistema cardiovascolare
US5605908A (en) * 1994-10-24 1997-02-25 Eli Lilly And Company Heterocyclic compounds and their use
US5998404A (en) * 1994-10-24 1999-12-07 Eli Lilly And Company Heterocyclic compounds and their use
US5602120A (en) * 1994-12-12 1997-02-11 Allelix Biopharmaceuticals, Inc. Benzyl-substituted compounds having dopamine receptor affinity
FR2741074B1 (fr) * 1995-11-09 1997-12-19 Adir Nouveaux composes tetracycliques de la 1,4-oxazine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
US5750556A (en) * 1996-10-30 1998-05-12 American Home Products Corporation 2-(aminomethyl)-3,4,7,9-tetrahydro-2H-pyrano- 2,3-E!indol-8-ones and derivatives
US6331543B1 (en) * 1996-11-01 2001-12-18 Nitromed, Inc. Nitrosated and nitrosylated phosphodiesterase inhibitors, compositions and methods of use
US5972958A (en) * 1997-02-18 1999-10-26 American Home Products Corporation 4-aminoalkoxy-1,3-dihydro-benzoimidazol-2-thiones
US5861423A (en) * 1997-02-21 1999-01-19 Caldwell; William Scott Pharmaceutical compositions incorporating aryl substituted olefinic amine compounds
DK0975347T3 (da) * 1997-02-28 2008-06-16 Nycomed Gmbh Synergistisk kombination af PDE-inhibitorer og adenylatcyclase-agonister eller guanylcyclyseagonister
FR2767825A1 (fr) * 1997-09-01 1999-02-26 Adir Nouvelles trans-3,4,4a,5,6,10b-hexahydro-2h-napht°1,2-b!-1, 4-oxazines disubstituees, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
US5973182A (en) * 1998-10-22 1999-10-26 Sepracor Inc. Carbonate Intermediates useful in the preparation of optically active cyclohexylphenylglycolate esters
US6469172B2 (en) * 2000-03-08 2002-10-22 Merck & Co., Inc. Process for the preparation of chemical compounds
GB0009583D0 (en) * 2000-04-18 2000-06-07 Glaxo Group Ltd Respiratory formulations
PE20020547A1 (es) * 2000-10-24 2002-06-12 Upjohn Co Uso de la tolterodina en tratamientos del asma
CA2448363A1 (en) * 2001-05-25 2002-12-05 Boehringer Ingelheim Pharma Gmbh & Co. Kg Combination of a pde4 inhibitor and tiotropium or derivate thereof for treating obstructive airways
JP2004538267A (ja) * 2001-05-25 2004-12-24 ベーリンガー インゲルハイム ファルマ ゲゼルシャフト ミット ベシュレンクテル ハフツング ウント コンパニー コマンディトゲゼルシャフト 閉塞性気道疾患及びその他の炎症性疾患を治療するためのドーパミンｄ２−受容体アゴニスト及びチオトロピウム又はその誘導体の組み合わせ
MXPA04003865A (es) * 2001-10-26 2004-07-08 Upjohn Co Compuestos de amonio cuaternario y sus usos como agentes antimuscarinicos.
US7005449B2 (en) * 2002-04-23 2006-02-28 Pharmacia & Upjohn Company Tolterodine salts

Also Published As

Publication number Publication date
JP2006523674A (ja) 2006-10-19
WO2004091596A2 (en) 2004-10-28
US20040209916A1 (en) 2004-10-21
CA2522666A1 (en) 2004-10-28
WO2004091596A3 (en) 2005-04-07
MXPA05011225A (es) 2005-12-14
EP1620083A2 (en) 2006-02-01

Similar Documents

Publication Publication Date Title
Beasley Jr et al. Efficacy of olanzapine: an overview of pivotal clinical trials
Bulut et al. Venlafaxine versus amitriptyline in the prophylactic treatment of migraine: randomized, double-blind, crossover study
ES2258251T3 (es) Reboxetina para tratar la fibromialgia y otros trastornos somatoformes.
Massana Reboxetine versus fluoxetine: an overview of efficacy and tolerability
Werling et al. A comparison of the binding profiles of dextromethorphan, memantine, fluoxetine and amitriptyline: treatment of involuntary emotional expression disorder
BRPI0409492A (pt) terapias de combinação
WO2001015678A2 (en) Topical use of kappa opioid agonists to treat otic pain
BR0315681A (pt) Composto e seus sais e hidratos farmaceuticamente aceitáveis, composição farmacêutica, métodos para o tratamento de doenças mediadas pela prostaglandina d2, para o tratamento de congestão nasal, para o tratamento de asma alérgica, e para o tratamento de rinite alérgica, composto ou um seu sal ou solvato farmaceuticamente aceitável, sal ou hidrato do composto, e, uso de um composto ou de um seu sal ou solvato farmaceuticamente aceitável
BRPI0517891A (pt) composições compreendendo azelastina e métodos de uso das mesmas
MY130803A (en) New quinuclidine amide derivatives
JP2002520273A5 (pt)
HUP0101543A2 (hu) Női szexuális zavarok kezelésére szolgáló gyógyszerkészítmények
BR0302965A (pt) Composto e método de tratar doenças mediadas por receptores de adenosina a2b
KR970701544A (ko) 5-HT_2 길항제를 사용하는 강박반응의 치료법(Treatment of obsessive-compulsive disorders with 5-HT_2 antagonists)
Davis et al. Ziprasidone
BR112014012628A2 (pt) di-hidrodiazepinocarbazolonas tetra ou pentacíclicas fundidas como inibidoras de parp
UA85541C2 (ru) Карбаматные производные хинуклидина и фармацевтическая композиции, которая содержит эти соединения
BRPI0413693A (pt) composição farmacêutica para a prevenção e tratamento da viciação em um mamìfero
JP2013519705A5 (pt)
JP2005298448A (ja) アズレン含有水性液剤
BR0315346A (pt) Método para o tratamento ou prevenção de sintomas de vasomotores em um paciente, formulação farmacêutica e utilização de inibidor de re-apreensão de norepinefrina em combinação com antagonista de 5-h2a
Kirwin et al. Duloxetine: A dual serotonin‐norepinephrine reuptake inhibitor for treatment of major depressive disorder
BR0317771A (pt) Composição farmacêutica, uso da mesma, e, método de tratar distúrbios em um paciente
JP5052028B2 (ja) アシタザノラスト含有組成物
JP4771675B2 (ja) コンタクトレンズ用組成物

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]